About Legal Wolverine
A reading of the BPC-157 TB-500 record drawn like a drafting sheet — the measured findings drawn solid, the gaps drawn dashed, the regulatory status kept in the title block.
What this site is
Legal Wolverine is a drafting sheet for the peer-reviewed research and the public FDA regulatory record on the BPC-157 TB-500 blend — a reading of the record, not a service built on it. It runs no clinic and employs no clinicians; it gives no medical advice and makes, sells, or ships nothing. What it does is draw each finding to scale from published science and public regulatory documents, and cite every one.
The name carries a drafting-table conceit, and it is deliberate. We treat the Wolverine blend as what it actually is — a two-component assembly whose individual parts have measured records and whose joint does not. Established single-component findings are drawn as solid edges; the unproven combination and the missing human data are drawn dashed. The honesty is in the line-style, not buried in a caveat.
What "legal" means here
The word legal in this site's name is editorial framing, not a service we offer and not a legal opinion we provide. It marks the position this publisher takes relative to the literature: we keep the regulatory and access record — FDA approval status, the withdrawn BPC-157 and TB-500 nominations with their safety concerns retained, the separate requirement for individual prescription review, and the WADA prohibition — as a specification block on the Wolverine legal status and 503A compounding page.
We do not offer legal advice, medical advice, treatment, consultation, or prescription services, and we do not sell or supply any substance. Everything here is general information about the published science and the public regulatory landscape. Where the regulatory record has gaps, we name the missing evidence and never present an advisory discussion as a final listing decision.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation in the Wolverine blend references: the peer-reviewed component studies, the 2025-2026 systematic reviews, and the FDA sources. We do not present rodent results as human expectations, we do not present a fixed-ratio vial as a validated dose, and we do not present the marketed synergy as proven — because no controlled combination study exists.
Where the literature is strong, we say so: BPC-157's transected-Achilles tendon data and VEGFR2-Akt-eNOS angiogenesis are well characterized, and Thymosin Beta-4's migration and wound-healing activity is consolidated in review. Where it is thin or absent — human combination efficacy, combination safety, a defined synergy ratio — we mark the gap rather than paper over it. That is the whole editorial posture: a precise reading of a two-part record, drawn to scale.